Milk fat globule--epidermal growth factor--factor VIII (MFGE8)/lactadherin promotes bladder tumor development.
Milk fat globule-epidermal growth factor-factor VIII (MFGE8), also called lactadherin or SED1, is a secreted integrin-binding protein that promotes elimination of apoptotic cells by phagocytes leading to tolerogenic immune responses, and vascular endothelial growth factor (VEGF)-induced angiogenesis: two important processes for cancer development. Here, by transcriptomic analysis of 228 biopsies of bladder carcinomas, we observed overexpression of MFGE8 during tumor development, correlated with expression of genes involved in cell adhesion or migration and in immune responses, but not in VEGF-mediated angiogenesis. To test whether MFGE8 expression was instrumental in bladder tumor development, or a simple consequence of this development, we used genetic ablation in a mouse model of carcinogen-induced bladder carcinoma. We showed that Mfge8 was also upregulated in mouse carcinoma, and that in its absence, Mfge8-deficient animals developed less advanced tumors. Angiogenesis was similar in carcinogen-treated Mfge8-expressing or -deficient bladders, thus ruling out a major role of the proangiogenic function of Mfge8 for its protumoral role. By contrast, the tumor-promoting role of Mfge8 was not observed anymore in mice devoid of adaptive immune system, and human tumors overexpressing MFGE8 where invaded with macrophages and regulatory T cells, thus suggesting that MFGE8/lactadherin favors development of bladder tumors at least partly by an immune system-dependent mechanism. Our observations suggest future use of MFGE8-inhibiting molecules as therapies of bladder carcinomas, and of a limited number of other human cancers, in which our analysis of public databases also revealed overexpression of MFGE8.
Institut Curie Research Center, Paris, France.
G
G
Sugano
I
I
Bernard-Pierrot
M
M
Laé
C
C
Battail
Y
Y
Allory
N
N
Stransky
S
S
Krumeich
M-L
ML
Lepage
P
P
Maille
M-H
MH
Donnadieu
C C
CC
Abbou
S
S
Benhamou
T
T
Lebret
X
X
Sastre-Garau
S
S
Amigorena
F
F
Radvanyi
C
C
Théry
D000818:Animals; D000954:Antigens, Surface / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D002085:Butylhydroxybutylnitrosamine / Q000008:administration & dosage; D002273:Carcinogens / Q000378:metabolism*; D002277:Carcinoma / Q000139:chemically induced / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D002448:Cell Adhesion / Q000276:immunology; D002471:Cell Transformation, Neoplastic; D020869:Gene Expression Profiling; D006801:Humans; D008264:Macrophages / Q000276:immunology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008894:Milk Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D009389:Neovascularization, Pathologic / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000276:immunology / Q000378:metabolism* / Q000473:pathology
D000954:Antigens, Surface; D002273:Carcinogens; C098942:MFGE8 protein, human; C490919:Mfge8 protein, mouse; D008894:Milk Proteins; D002085:Butylhydroxybutylnitrosamine